Clinical trial · Interventional
Glioblastoma Remote Monitoring and Care - Research Protocol
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Why stopped (as posted): PI decision
Summary
Brief summary (as posted)
The purpose of this research is to learn more about how what the Apple watch measures, in terms of walking data, heart rate, breathing rate, and sleep habits, relates to how participants feel. During the course of the treatment, the symptoms participants experience change, and whether the Apple watch can detect these changes. Ultimately, this knowledge is being used to design proactive tools and signatures that can predict complications or symptom changes before they happen.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Seizures | — | UNRESOLVED | — |
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apple Watch | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Wearing the Apple watch and the associated logging of health data
- description
- As part of the monitoring needed for this study, participants will be enrolled for at least 6 months, as this will give enough data to understand how the participant's health changes associate with what is measured by the Apple watch. After this 6 month period, participants may choose to end their participation on the study, or continue if they wish.
- interventionNames
- Device: Apple Watch
Primary outcomes (2)
- measure
- Success rate of 16-hour wear-time
- timeFrame
- 6 months
- description
- The wear time will be defined by the "wear detection" onboard the Apple Watch. Median value per day will be used to avoid biasing this estimate toward outlier days. A 16-hr wear-time requirement will be considered feasible for studies of the GBM patient population if results show that there is a greater than 90% likelihood (within the 90% confidence interval) that a member of the population.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * newly-diagnosed or recurrent glioblastoma undergoing treatment or active surveillance * at least 18 years of age at the time of study enrolment * Karnofsky Performance Status (KPS) ≥ 70% at time of study enrolment * able to comprehend informed consent form and provide informed consent * access to patient or caregiver's own Apple iPhone to interface with watch application for documentation of symptoms Exclusion Criteria: * under 18 years of age at the time of study enrolment * inability to give informed consent due to aphasia or other language barrier * tattoos located on the skin of the wrist or forearm where the Apple Watch will be placed or other skin conditions preventing adequate sensor function * inability to tolerate Apple Watch for at least 12 hours per day on at least 50% of days in a four-week period * no access to patient or caregiver Apple iPhone to document symptoms
References
Publications (0)
Data not yet available